- Home
- GRSD vs SCLX Comparison
GRSD vs SCLX Comparison
Compare GRSD & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRSD | SCLX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | Jersey | United States |
| Employees | N/A | 34 |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.3M | 55.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GRSD | SCLX |
|---|---|---|
| Price | $2.03 | $6.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 293.5K | 119.0K |
| Earning Date | N/A | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $4.20 |
| 52 Week High | $2.07 | $34.27 |
Technical Indicators
Market Signals| Indicator | GRSD | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 84.21 | N/A |
| Support Level | $1.75 | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.14 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 95.51 | 0.00 |
Price Performance
Historical ComparisonAbout SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.